Biotinylated Human HLA-A*11:01&B2M&EGFR WT (KITDFGLAK) Monomer Protein
Catalog No: TERT-HB002
- Species
- Human
- Expression System
- E. coli
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human HLA-A*11:01&B2M&EGFR WT (KITDFGLAK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and KITDFGLAK peptide (accession: AAV53343.1(HLA-A*11:01) & P61769(B2M) &KITDFGLAK).
Product Details
- Molecular Aliases
- TERT; ILAKFLHWL
- Protein Length
- Gly25-Thr305
- Expression System
- E. coli
- Theoretical Molecular Weight
- The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Biotinylated Human HLA-A*11:01&B2M&EGFR WT (KITDFGLAK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human HLA-A*11:01&B2M&EGFR WT (KITDFGLAK) Monomer is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human HLA-A*11:01&B2M&EGFR WT (KITDFGLAK) Monomer, His Avi tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for HLA-A*11:01&B2M&EGFR TCR, hFc Tag with the EC50 of 32.6ng/ml determined by ELISA. (QC Test)
Background
The human telomerase catalytic subunit human telomerase reverse transcriptase (hTERT) is expressed in many human cancer cells derived from multiple tissues, but infrequently in normal cells. Thus, hTERT is an attractive candidate target for tumor immunotherapy. hTERT:540–548 peptide (p540, ILAKFLHWL) has been identified as an effective HLA-A*0201-restricted T-cell epitope, an effective T-cell-based cancer treatment, including vaccines, against hTERT will likely require the identification of other MHC class I-restricted epitopes in this antigen.
References
- Huang G, Geng J, Wang R, Chen L. Identification of a new cytotoxic T-cell epitope p675 of human telomerase reverse transcriptase. Cancer Biother Radiopharm. 2012 Nov;27(9):600-5. doi: 10.1089/cbr.2012.1193. Epub 2012 Aug 23. PMID: 22917214.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.